The primary objective of the study was to determine the safety and tolerability of TACI-Ig in rheumatoid arthritis (RA) patients and to examine the relationship between TACI-Ig dose and schedule with markers of biologic activity and disease activity.
TACI-Ig appeared to be safe and well tolerated across the full range of dose levels and schedules tested in this study, and clear biologic responses were observed, which appeared to correlate with clinical benefit.
“The results of this study are very encouraging,” said Dr Nicole Onetto, chief medical officer of ZymoGenetics. “The clear biologic effects and excellent safety profile we have seen with TACI-Ig as well as the correlations between dose/schedule and biological activity will help us to optimize the design of future studies in RA and other diseases.”